Want to see LFMD full AI Analyst Report?
Top Page
LifeMD
(NASDAQ:LFMD)
Select Model
Select Model
Rating:58Neutral
Price Target:
$5.00
▲(79.86% Upside)
Action:Reiterated
Date:06/23/26
The score is driven primarily by improved cash generation and constructive earnings-call guidance (reaffirmed FY2026 targets and a path to H2 adjusted EBITDA profitability), supported by a positive technical setup with the stock trading above key moving averages. These positives are tempered by persistent GAAP/net losses, recent revenue volatility (sharp TTM decline), and limited valuation support due to a negative P/E and no dividend.
Positive Factors
Subscriber Growth & Recurring Revenue
Consistent, large subscriber additions strengthen LifeMD’s direct-to-patient recurring revenue base. A growing active subscriber pool improves predictability, enables higher lifetime value via cross-sell, and amplifies scale benefits for marketing efficiency and retention-driven margin improvement over the medium term.
Negative Factors
Persistent GAAP Net Losses
Ongoing GAAP losses signal the company has not yet translated strong gross margins and subscriber growth into consistent bottom-line profitability. Continued net losses can erode equity, constrain reinvestment capacity, and increase reliance on external financing if operating improvements and marketing normalization do not materialize as planned.
Read all positive and negative factors
Positive Factors
Negative Factors
Subscriber Growth & Recurring Revenue
Consistent, large subscriber additions strengthen LifeMD’s direct-to-patient recurring revenue base. A growing active subscriber pool improves predictability, enables higher lifetime value via cross-sell, and amplifies scale benefits for marketing efficiency and retention-driven margin improvement over the medium term.
Read all positive factors
LifeMD (LFMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$199.74M
Dividend YieldN/A
Average Volume (3M)958.69K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth-6.23%
EPS Growth-25.01%
CountryUS
Employees304
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.41
Shares Outstanding48,362,510
10 Day Avg. Volume969,479
30 Day Avg. Volume958,693
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)6.65
Price to Sales (P/S)0.79
P/FCF Ratio-124.26
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue0.95
Enterprise Value/Gross Profit1.11
Enterprise Value/Ebitda-49.59
Forecast
1Y Price Target
$9.50Price Target Upside241.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$222.05M
LifeMD Business Overview & Revenue Model
Company Description
LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, i...
How the Company Makes Money
LifeMD generates revenue primarily from selling telehealth-based medical services and related programs directly to consumers. Key revenue streams generally include (1) patient fees for virtual visits and ongoing care programs (often structured as ...
LifeMD Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call presents a constructive operational narrative: record subscriber additions, strong momentum in weight management and Women’s Health, meaningful gross margin expansion, growing pharmacy and insurance scale, and a clear roadmap to leverage AI for operating leverage. These positives are balanced against near-term profitability pressures from a front-loaded marketing push, a product‑mix transition from compounded to branded drugs that dampened near‑term revenue/unit economics, a wider GAAP net loss, and negative adjusted EBITDA in Q1. Management reaffirmed full-year guidance and outlined drivers for a second‑half EBITDA ramp (insurance coverage expansion, pharmacy economics, cross-sell, and marketing normalization), indicating confidence in the outlook despite short-term investments and transitions.Positive Updates
Revenue Ahead of Guidance
Q1 revenue of $50.2M, above guidance of $48M-$49M; full-year guidance reaffirmed at $220M-$230M (13%-19% YoY growth) with expected annualized run-rate revenue >$250M by Q4.
Negative Updates
Flat Year‑Over‑Year Revenue
Q1 revenue was essentially flat YoY at $50.2M versus $50.9M in the prior-year period, reflecting a product-mix shift (migration from compounded GLP-1s to branded drugs) that reduced near-term revenue per unit.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Ahead of Guidance
Q1 revenue of $50.2M, above guidance of $48M-$49M; full-year guidance reaffirmed at $220M-$230M (13%-19% YoY growth) with expected annualized run-rate revenue >$250M by Q4.
Read all positive updates
Company Guidance
Management reaffirmed full-year 2026 guidance of $220–$230 million in revenue (≈13–19% YoY) and $12–$17 million in adjusted EBITDA, and reiterated a goal of annualized run-rate revenue above $250 million and adjusted EBITDA above $25 million by Q4; Q2 guidance is $47–$50 million in revenue and adjusted EBITDA of negative $2 million to positive $1 million with a return to adjusted EBITDA profitability expected in H2. For context, Q1 actuals included $50.2 million revenue, ~42k net subscriber adds (ending >365k active subscribers, +~26% YoY), an adjusted EBITDA loss of ~$4.5 million, GAAP net loss of $9.6 million ($0.20/sh), gross profit $44.2 million with gross margin of 88% (up ~420 bps), selling & marketing $29.8 million, stock‑based comp $1.4 million, cash of $34.5 million, no debt and a $30 million undrawn revolver. Other operational metrics cited: ~100k weight‑management patients, ~215k RexMD active patients, pharmacy processing ~20k scripts/month from a 22.5k sq ft facility, ~112 million covered lives at quarter end (expected ~230 million by month‑end), CAC improved 4–5% sequentially as volumes rose from ~300–400 to 600–1,000 new patients/day, Women’s Health subscribers grew >7x from Q4 with on‑therapy retention >80%, RexMD personalized ED meds +>40% vs Q4, and marketing is expected at ~$26–27 million in Q2 with combined Q3–Q4 marketing of ~$42–44 million.LifeMD Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
56
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 219.42M | 194.06M | 212.45M | 152.55M | 119.03M | 92.88M |
| Gross Profit | 188.46M | 154.76M | 188.39M | 133.65M | 100.37M | 74.88M |
| EBITDA | -4.22M | -1.52M | -6.65M | -8.21M | -38.60M | -57.94M |
| Net Income | -16.25M | -7.11M | -18.88M | -20.60M | -45.54M | -60.90M |
Balance Sheet | ||||||
| Total Assets | 70.12M | 70.41M | 72.46M | 58.48M | 25.67M | 49.92M |
| Cash, Cash Equivalents and Short-Term Investments | 34.48M | 36.79M | 35.00M | 33.15M | 3.96M | 41.33M |
| Total Debt | 6.17M | 6.32M | 25.10M | 18.93M | 4.13M | 1.85M |
| Total Liabilities | 55.09M | 47.25M | 76.51M | 52.91M | 32.97M | 24.10M |
| Stockholders Equity | 15.04M | 23.16M | -5.49M | 3.51M | -6.83M | 26.85M |
Cash Flow | ||||||
| Free Cash Flow | 14.83M | -1.24M | 5.98M | 86.95K | -35.83M | -36.49M |
| Operating Cash Flow | 5.66M | 8.28M | 17.51M | 8.82M | -22.94M | -33.09M |
| Investing Cash Flow | 7.72M | 6.91M | -11.54M | -8.73M | -13.91M | -3.40M |
| Financing Cash Flow | -13.29M | -13.41M | -4.12M | 29.10M | -528.20K | 68.64M |
LifeMD Technical Analysis
Negative
2.78
Price Trends
4.59
Negative
3.99
Positive
4.40
Negative
Market Momentum
-0.04
Positive
40.50
Neutral
12.86
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFMD, the sentiment is Negative. The current price of 2.78 is below the 20-day moving average (MA) of 4.67, below the 50-day MA of 4.59, and below the 200-day MA of 4.40, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 40.50 is Neutral, neither overbought nor oversold. The STOCH value of 12.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFMD.
LifeMD Risk Analysis
LifeMD disclosed 45 risk factors in its most recent earnings report. LifeMD reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LifeMD Peers Comparison
UnderperformOutperform
Sector (51)
LFMD
LifeMD
4.13
-9.49
-69.68%
PETS
Petmed Express
1.76
-1.56
-46.99%
YI
111
4.08
-3.06
-42.86%
LifeMD Corporate Events
Business Operations and StrategyProduct-Related Announcements
LifeMD Partners with Antares on XYOSTED Telehealth Program
Positive
Jun 22, 2026
On June 22, 2026, LifeMD announced a strategic co-marketing collaboration with Halozyme’s subsidiary Antares Pharma to support a direct-to-patient, self-pay program for XYOSTED, the only FDA-approved once-weekly subcutaneous testosterone aut...
Business Operations and StrategyFinancial Disclosures
LifeMD Posts Q1 Results, Reaffirms 2026 Profitability Outlook
Positive
May 6, 2026
LifeMD reported first-quarter 2026 results on May 6, 2026, with revenue of $50.2 million, slightly below the prior year but above guidance, and an adjusted EBITDA loss of $4.5 million in line with expectations, driven by elevated, front-loaded mar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.